Acetylcysteine
- Generic Name
- Acetylcysteine
- Brand Names
- Acetadote
- Drug Type
- Small Molecule
- Chemical Formula
- C5H9NO3S
- CAS Number
- 616-91-1
- Unique Ingredient Identifier
- WYQ7N0BPYC
- Background
Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.
Acetylcysteine was granted FDA approval on 14 September 1963.
- Indication
Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.
- Associated Conditions
- Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis
- Associated Therapies
- Airway secretion clearance therapy
Efficacy of N-acetylcysteine Versus Placebo as Prophylaxis of Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Instituto Brasileiro de Controle do Cancer
- Target Recruit Count
- 80
- Registration Number
- NCT04712435
- Locations
- 🇧🇷
Jamilla Neves Cavalcante, Sao Paulo, SP, Brazil
Efficacy and Safety of Rifaximin With NAC in IBS-D
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 45
- Registration Number
- NCT04557215
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
- Conditions
- Interventions
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Cambridge Health Alliance
- Target Recruit Count
- 165
- Registration Number
- NCT04419025
- Locations
- 🇺🇸
CHA Respiratory Clinic, Somerville, Massachusetts, United States
🇺🇸CHA Everett Hospital, Everett, Massachusetts, United States
🇺🇸CHA Cambridge Hospital, Cambridge, Massachusetts, United States
A Study of N-acetylcysteine in Patients With COVID-19 Infection
- Conditions
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT04374461
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Combination of High-dose Dexamethasone and Acetylcysteine as the Treatment of Newly-diagnosed ITP
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT04368598
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 24
- Registration Number
- NCT04278898
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Neurocircuit Strategy to Decrease Cocaine Cue Reactivity
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 62
- Registration Number
- NCT04155632
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 944
- Registration Number
- NCT04123405
- Locations
- 🇷🇺
Sandoz Investigative Site, Yaroslavl, Russian Federation
Effect of Acetaminophen and N-Acetylcysteine on Liver Metabolism on Homocystinuria
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 10
- Registration Number
- NCT04015557
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Mucpharm Pty Ltd
- Target Recruit Count
- 62
- Registration Number
- NCT03976973
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.